Sumitomo Pharma and Poxel AnnounceTopline Results from Post-MarketingClinical Study on TWYMEEG® for the Treatment of Type 2 Diabetes in Japan

7 août 2024

Sumitomo Pharma and Poxel reported that a post-marketing study of TWYMEEG® in Japanese type 2 diabetes patients with renal impairment showed a safety profile consistent with previous trials, supporting plans to discuss updating the drug’s label with regulators in 2024.

Osaka, Japan & Lyon, France, aug 07, 2024 – Sumitomo Pharma and Poxel Announce Topline Results from Post-Marketing Clinical Study on TWYMEEG® for the Treatment of Type 2 Diabetes in Japan

Download Poxel Press Release